

Jose Angel Garcia-Saenz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/899644/publications.pdf>

Version: 2024-02-01

107
papers

6,396
citations

147566

31
h-index

76769

74
g-index

114
all docs

114
docs citations

114
times ranked

9817
citing authors

#	ARTICLE	IF	CITATIONS
1	Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor. <i>Clinical Cancer Research</i> , 2022, 28, 1107-1116.	3.2	7
2	HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping. <i>Cancers</i> , 2022, 14, 512.	1.7	2
3	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. <i>Breast Cancer Research</i> , 2022, 24, 2.	2.2	15
4	Abstract P2-01-18: Orthogonal assessment of <i>PIK3CA</i> and <i>ESR1</i> mutation detection in longitudinal cfDNA samples from endocrine-resistant HR+/HER2- advanced breast cancer patients using dPCR and NGS-based SafeSEQ technology. <i>Cancer Research</i> , 2022, 82, P2-01-18-P2-01-18.	0.4	0
5	Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study. <i>European Journal of Clinical Nutrition</i> , 2022, 76, 1343-1346.	1.3	3
6	Abstract P5-18-02: Final findings from the CONTROL trial of diarrheal prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer. <i>Cancer Research</i> , 2022, 82, P5-18-02-P5-18-02.	0.4	1
7	Abstract P3-05-06: Genome-wide DNA methylation analysis identifies novel biomarkers associated with risk of relapse beyond oncoTYPE DX recurrence-score risk assessment within HR+/HER2- early-stage breast cancer patients. <i>Cancer Research</i> , 2022, 82, P3-05-06-P3-05-06.	0.4	0
8	Abstract GS4-10: Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, <i>HER2</i> -mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial. <i>Cancer Research</i> , 2022, 82, GS4-10-GS4-10.	0.4	6
9	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. <i>Oncologist</i> , 2022, 27, e561-e570.	1.9	5
10	Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy. <i>JAMA Oncology</i> , 2022, 8, 1190.	3.4	21
11	EPIK-B5: A phase III, randomized study of alpelisib (ALP) plus fulvestrant (FUL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i> -mutated advanced breast cancer (ABC) progressing on/after an aromatase inhibitor (AI) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS1109-TPS1109.	0.8	2
12	Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 462-470.	2.3	6
13	Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 443-452.	3.0	22
14	Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. <i>Oncologist</i> , 2021, 26, e53-e65.	1.9	64
15	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , 2021, 12, 1078.	5.8	19
16	Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts. <i>Scientific Reports</i> , 2021, 11, 7064.	1.6	13
17	In Reply. <i>Oncologist</i> , 2021, 26, e1286-e1287.	1.9	0
18	Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.. <i>Journal of Clinical Oncology</i> , 2021, 39, 518-518.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).. Journal of Clinical Oncology, 2021, 39, 517-517.	0.8	3
20	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203.	2.6	6
21	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86.	2.2	7
22	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer, 2021, 125, 1135-1145.	2.9	9
23	Trajectories of alcohol consumption during life and the risk of developing breast cancer. British Journal of Cancer, 2021, 125, 1168-1176.	2.9	17
24	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 623-642.	1.1	19
25	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. Scientific Reports, 2021, 11, 19787.	1.6	2
26	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	9.4	120
27	Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). Journal of Clinical Oncology, 2020, 38, 203-213.	0.8	87
28	GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID 19 Pandemic in Spain. Oncologist, 2020, 25, e1339-e1345.	1.9	14
29	Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study. Scientific Reports, 2020, 10, 7741.	1.6	9
30	Association Between <i>ABCB1</i> Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast Cancer. JAMA Dermatology, 2020, 156, 987.	2.0	8
31	Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer. Future Oncology, 2020, 16, 2763-2778.	1.1	8
32	Serum Phospholipids Fatty Acids and Breast Cancer Risk by Pathological Subtype. Nutrients, 2020, 12, 3132.	1.7	11
33	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	2.6	39
34	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	9.4	265
35	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	1.6	2
36	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. Genetic Epidemiology, 2020, 44, 442-468.	0.6	32

#	ARTICLE	IF	CITATIONS
37	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. <i>Nature Communications</i> , 2020, 11, 312.	5.8	30
38	Monitoring of PIK3CA and ESR1 mutations in circulating tumor DNA as predictive and prognostic biomarkers in patients with endocrine-resistant ER+/HER2- advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e13045-e13045.	0.8	0
39	Serum phospholipids fatty acids and breast cancer risk by pathological subtype: EpiGEICAM study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e13604-e13604.	0.8	0
40	A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012â€™12 (EDALINE) study. <i>Investigational New Drugs</i> , 2019, 37, 98-108.	1.2	33
41	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 38.	2.3	28
42	Two truncating variants in FANCC and breast cancer risk. <i>Scientific Reports</i> , 2019, 9, 12524.	1.6	5
43	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	5.8	88
44	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019, 10, 1741.	5.8	90
45	Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study. <i>Scientific Reports</i> , 2019, 9, 3904.	1.6	23
46	Genome-wide association study of germline variants and breast cancer-specific mortality. <i>British Journal of Cancer</i> , 2019, 120, 647-657.	2.9	52
47	Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study. <i>Breast Journal</i> , 2019, 25, 219-225.	0.4	7
48	A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors. <i>Frontiers in Immunology</i> , 2019, 10, 2802.	2.2	24
49	Concordance of Genomic Variants in Matched Primary Breast Cancer, Metastatic Tumor, and Circulating Tumor DNA: The MIRROR Study. <i>JCO Precision Oncology</i> , 2019, 3, 1-16.	1.5	7
50	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019, 104, 21-34.	2.6	711
51	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 134, 39-45.	2.0	200
52	SEOM clinical guidelines in early stage breast cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 18-30.	1.2	48
53	Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2018, 110, 560-567.	3.0	206
54	Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. <i>Clinical Cancer Research</i> , 2018, 24, 1845-1852.	3.2	84

#	ARTICLE	IF	CITATIONS
55	Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 249-256.	1.1	23
56	Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 245-250.	0.7	3
57	Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. <i>Clinical Cancer Research</i> , 2018, 24, 5820-5829.	3.2	82
58	The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of indolent stage IV disease (Stage IV indolent).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1019-1019.	0.8	3
59	Dietary inflammatory index and breast cancer risk by menopausal status and histological subtype.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1521-1521.	0.8	8
60	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. <i>Clinical Cancer Research</i> , 2017, 23, 649-657.	3.2	108
61	Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging. <i>BMC Cancer</i> , 2017, 17, 210.	1.1	59
62	Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 473-480.	0.4	18
63	Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 181-189.	1.1	11
64	Physical activity and breast cancer risk by pathological subtype. <i>Gynecologic Oncology</i> , 2017, 144, 577-585.	0.6	34
65	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	13.7	1,099
66	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	9.4	289
67	18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial. <i>Clinical Cancer Research</i> , 2017, 23, 1432-1441.	3.2	32
68	Critically short telomeres and toxicity of chemotherapy in early breast cancer. <i>Oncotarget</i> , 2017, 8, 21472-21482.	0.8	14
69	Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 507-515.	1.1	27
70	Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study. <i>European Journal of Cancer</i> , 2016, 58, 122-129.	1.3	8
71	A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Fluorouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 289-296.	0.4	24
72	Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile. <i>Current Cancer Drug Targets</i> , 2016, 16, 415-428.	0.8	10

#	ARTICLE	IF	CITATIONS
73	SEOM clinical guidelines in early-stage breast cancer 2015. <i>Clinical and Translational Oncology</i> , 2015, 17, 939-945.	1.2	18
74	Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction. <i>Translational Research</i> , 2015, 166, 783-787.	2.2	7
75	Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 1045-1052.	0.8	108
76	BRCA1 Alternative splicing landscape in breast tissue samples. <i>BMC Cancer</i> , 2015, 15, 219.	1.1	17
77	Standard Versus Continuous Administration of Capecitabine in Metastatic Breast Cancer (GEICAM/2009-05): A Randomized, Noninferiority Phase II Trial With a Pharmacogenetic Analysis. <i>Oncologist</i> , 2015, 20, 111-112.	1.9	20
78	Abstract OT1-1-06: A phase I study of LDE225 in combination with docetaxel in patients with triple negative (TN) advanced breast cancer (ABC): GEICAM/2012-12 (EDALINE study). , 2015, , .		1
79	Abstract P5-19-21: TRASTYVERE study: A retrospective analysis of HER2-positive metastatic breast cancer (MBC) patients treated in Spain with lapatinib (L) plus trastuzumab (T). , 2015, , .		0
80	Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer. <i>Journal of Cancer Research and Therapeutics</i> , 2014, 10, 967.	0.3	1
81	Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study. <i>BMC Cancer</i> , 2014, 14, 166.	1.1	23
82	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 406-414.	5.1	703
83	Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3626-3633.	0.8	118
84	Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2014, 33, 14-21.	0.0	9
85	Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1823-1829.	0.5	281
86	A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 939-946.	1.1	42
87	Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelial ovarian cancer patients. Long-term single institution experience and literature review. <i>Clinical and Translational Oncology</i> , 2011, 13, 121-132.	1.2	8
88	Is trastuzumab-induced cardiotoxicity involved in onco-cardiology outcome?. <i>Clinical and Translational Oncology</i> , 2011, 13, 451-459.	1.2	2
89	A Polymorphism in the <i>Cytidine Deaminase</i> Promoter Predicts Severe Capecitabine-Induced Hand-Foot Syndrome. <i>Clinical Cancer Research</i> , 2011, 17, 2006-2013.	3.2	75
90	Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 169-176.	1.1	69

#	ARTICLE	IF	CITATIONS
91	Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations. <i>Oncologist</i> , 2009, 14, 1-11.	1.9	124
92	Circulating tumour cells in locally advanced breast cancer. <i>Clinical and Translational Oncology</i> , 2009, 11, 544-547.	1.2	11
93	Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , 2009, 11, 737-747.	1.2	9
94	Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , 2009, 11, 737-47.	1.2	3
95	Irinotecan in the treatment of elderly patients with advanced colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 68, 250-255.	2.0	8
96	Successful rectal cancer local recurrence radiofrequency ablation. <i>Clinical and Translational Oncology</i> , 2008, 10, 300-302.	1.2	1
97	Elementary, My Dear Watson. <i>Journal of Clinical Oncology</i> , 2007, 25, 1815-1816.	0.8	8
98	Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. <i>Lancet Oncology</i> , The, 2007, 8, 219-225.	5.1	181
99	Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid. <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2007, 12, E351-6.	0.7	14
100	Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies. <i>Clinical and Translational Oncology</i> , 2006, 8, 50-53.	1.2	13
101	Significance of the immunohistochemical detection of lymph node micrometastases in Stage II Colorectal Carcinoma. <i>Clinical and Translational Oncology</i> , 2006, 8, 676-680.	1.2	14
102	New target-based agents involve new clinical trial designs. <i>Clinical and Translational Oncology</i> , 2006, 8, 581-587.	1.2	0
103	Circulating tumoral cells lack circadian-rhythm in hospitalized metastatic breast cancer patients. <i>Clinical and Translational Oncology</i> , 2006, 8, 826-829.	1.2	7
104	Chemotherapy for gastric cancer. <i>World Journal of Gastroenterology</i> , 2006, 12, 204.	1.4	88
105	Trastuzumab Associated with Successive Cytotoxic Therapies Beyond Disease Progression in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 6, 325-329.	1.1	46
106	Vinorelbine as a 96-Hour Continuous Infusion in Heavily Pretreated Patients with Metastatic Breast Cancer: A Cooperative Study by the GEICAM Group. <i>Clinical Breast Cancer</i> , 2003, 3, 399-404.	1.1	14
107	Methotrexate, Uracil and Tegafur, and Leucovorin Chemotherapy for Patients With Breast Cancer in Progression After High-Dose Chemotherapy With Peripheral Blood Progenitor Cell Transplant. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000, 23, 617-621.	0.6	4